ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
LONG-TERM TESTOSTERONE TREATMENT IMPROVES LIVER FUNCTION PARAMETERS IN MEN WITH FUNCTIONAL HYPOGONADISM
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 222683" data-attributes="member: 13851"><p><strong>LONG-TERM TESTOSTERONE TREATMENT IMPROVES LIVER FUNCTION PARAMETERS IN MEN WITH FUNCTIONAL HYPOGONADISM: REAL-WORLD DATA FROM A REGISTRY (2022)</strong></p><p><em>Ahmad Haider, Karim Haider, Farid Saad, Gheorghe Doros, Abdulmaged Traish, Private Urology Practice, Bremerhaven, Germany Consultant, Bayer AG, Berlin, Germany Research Department, Guld Medical University, Ajman, UAE Department of Epidemiology and Statistics, Boston University School of Public Health, Boston, MA, USA Department of Biochemistry and Department of Urology, Boston University School of Medicine, Boston, MA, USA</em></p><p></p><p></p><p><strong>Introduction and Objectives:</strong><em> The prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with hypogonadism is high. Most of these patients are overweight or obese. </em></p><p></p><p><strong>Methods:</strong><em> In a registry of 796 men with symptomatic functional hypogonadism, 394 men (49.5%) received testosterone therapy (TTh) by testosterone undecanoate (TU) injections of 1000mg/12weeks following an initial 6-week interval (T-group). 402 men opted against TTh and served as controls (CTRL). 13-year data are presented. Means and standard deviations of absolute measures over 13 years are reported. Fatty liver index (FLI) was calculated using the formula by Bedogni. </em></p><p></p><p><strong>Results: </strong><em>Mean age at baseline: 60.9±6.0 years (T-group: 58.5±6.3, CTRL: 63.2±4.8). Mean (median) follow-up: T-group 10.1±3.0(11), CTRL 10.5±3.0(12) years. γ-GT (U/L) decreased from 45.3±26.2 to 21.1±6.8 in the T-group and increased from 34.8±11.3 to 62.0±6.9 in CTRL (p<0.0001 for both).</em></p><p><em></em></p><p><em></em></p><p><em><strong>*<u>Triglycerides</u> decreased from 3.2±0.6 to 2.2±0.1 in the T-group and increased from 3.0±0.5 to 3.7±0.6 in </strong></em></p><p><em><strong>CTRL (p<0.0001 for both). </strong></em></p><p><em><strong></strong></em></p><p><em><strong>*<u>Waist circumference</u> (cm) decreased from 110.9±13.7 to 96.1±5.1 in the T- group (p<0.0001) and increased in CTRL from 111.0±11.8 to 114.3±8.3 (p<0.0001).</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*<u>BMI</u> (kg/m²) decreased from 34.2±5.4 to 27.5±2.4 in the T-group (p<0.0001) and increased in CTRL from 30.5±4.4 to 31.6±3.4 (p<0.0001). </strong></em></p><p><em><strong></strong></em></p><p><em><strong>*<u>AST</u> (U/L) decreased from 39.7±15.1 to 20.7±2.0 in the T-group and increased from 26.9±8.3 to 52.7±9.8 in CTRL (p<0.0001 for both). </strong></em></p><p><em><strong></strong></em></p><p><em><strong>*<u>ALT</u> (U/L) decreased from 42.7±14.9 to 24.6±2.3 in the T-group and increased from 31.1±8.6 to 58.6±12.0 in CTRL (p<0.0001 for both). </strong></em></p><p><em><strong></strong></em></p><p><em><strong>*<u>FLI</u> decreased from 89.9±11.0 to 57.0±13.0 in the T-group and increased from 84.3±13.4 to 94.2±5.2 in CTRL (p<0.0001 for both).</strong></em></p><p></p><p></p><p></p><p></p><p><strong>Conclusion:</strong><em><strong> Long-term testosterone therapy in men with functional hypogonadism improved surrogate parameters of liver function indicating an improvement in NAFLD. All parameters deteriorated in untreated controls.</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 222683, member: 13851"] [B]LONG-TERM TESTOSTERONE TREATMENT IMPROVES LIVER FUNCTION PARAMETERS IN MEN WITH FUNCTIONAL HYPOGONADISM: REAL-WORLD DATA FROM A REGISTRY (2022)[/B] [I]Ahmad Haider, Karim Haider, Farid Saad, Gheorghe Doros, Abdulmaged Traish, Private Urology Practice, Bremerhaven, Germany Consultant, Bayer AG, Berlin, Germany Research Department, Guld Medical University, Ajman, UAE Department of Epidemiology and Statistics, Boston University School of Public Health, Boston, MA, USA Department of Biochemistry and Department of Urology, Boston University School of Medicine, Boston, MA, USA[/I] [B]Introduction and Objectives:[/B][I] The prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with hypogonadism is high. Most of these patients are overweight or obese. [/I] [B]Methods:[/B][I] In a registry of 796 men with symptomatic functional hypogonadism, 394 men (49.5%) received testosterone therapy (TTh) by testosterone undecanoate (TU) injections of 1000mg/12weeks following an initial 6-week interval (T-group). 402 men opted against TTh and served as controls (CTRL). 13-year data are presented. Means and standard deviations of absolute measures over 13 years are reported. Fatty liver index (FLI) was calculated using the formula by Bedogni. [/I] [B]Results: [/B][I]Mean age at baseline: 60.9±6.0 years (T-group: 58.5±6.3, CTRL: 63.2±4.8). Mean (median) follow-up: T-group 10.1±3.0(11), CTRL 10.5±3.0(12) years. γ-GT (U/L) decreased from 45.3±26.2 to 21.1±6.8 in the T-group and increased from 34.8±11.3 to 62.0±6.9 in CTRL (p<0.0001 for both). [B]*[U]Triglycerides[/U] decreased from 3.2±0.6 to 2.2±0.1 in the T-group and increased from 3.0±0.5 to 3.7±0.6 in CTRL (p<0.0001 for both). *[U]Waist circumference[/U] (cm) decreased from 110.9±13.7 to 96.1±5.1 in the T- group (p<0.0001) and increased in CTRL from 111.0±11.8 to 114.3±8.3 (p<0.0001). *[U]BMI[/U] (kg/m²) decreased from 34.2±5.4 to 27.5±2.4 in the T-group (p<0.0001) and increased in CTRL from 30.5±4.4 to 31.6±3.4 (p<0.0001). *[U]AST[/U] (U/L) decreased from 39.7±15.1 to 20.7±2.0 in the T-group and increased from 26.9±8.3 to 52.7±9.8 in CTRL (p<0.0001 for both). *[U]ALT[/U] (U/L) decreased from 42.7±14.9 to 24.6±2.3 in the T-group and increased from 31.1±8.6 to 58.6±12.0 in CTRL (p<0.0001 for both). *[U]FLI[/U] decreased from 89.9±11.0 to 57.0±13.0 in the T-group and increased from 84.3±13.4 to 94.2±5.2 in CTRL (p<0.0001 for both).[/B][/I] [B]Conclusion:[/B][I][B] Long-term testosterone therapy in men with functional hypogonadism improved surrogate parameters of liver function indicating an improvement in NAFLD. All parameters deteriorated in untreated controls.[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
LONG-TERM TESTOSTERONE TREATMENT IMPROVES LIVER FUNCTION PARAMETERS IN MEN WITH FUNCTIONAL HYPOGONADISM
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top